Personalis (NASDAQ:PSNL) Hits New 52-Week High – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL) shares reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $17.04 and last traded at $16.4580, with a volume of 2215499 shares traded. The stock had previously closed at $15.81.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of research reports. BTIG Research boosted their target price on shares of Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research note on Monday, July 20th. Needham & Company LLC lowered shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Zacks Research downgraded Personalis from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Finally, TD Cowen reissued a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.25.

Personalis Stock Performance

The company has a market cap of $1.75 billion, a P/E ratio of -15.31 and a beta of 2.27. The business has a fifty day simple moving average of $12.97 and a 200 day simple moving average of $9.57.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Equities research analysts expect that Personalis, Inc. will post -1.07 EPS for the current year.

Insider Buying and Selling at Personalis

In related news, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at $3,558,668.88. The trade was a 29.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock valued at $5,599,929 over the last three months. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd increased its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares in the last quarter. Deutsche Bank AG lifted its stake in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after acquiring an additional 2,395 shares during the last quarter. Howland Capital Management LLC increased its position in shares of Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after buying an additional 3,851 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.